- 英文名称((4S,5S)-2,2-Dimethyl-1,3-Dioxolane-4,5-Diyl)Dimethanol
- 中文名称(4S,5S)-2,2-二甲基-1,3-二氧戊环-4,5-二甲醇
- IUPAC名称((4S,5S)-2,2-dimethyl-1,3-dioxolane-4,5-diyl)dimethanol
- 其它别名(4S,5S)-4,5-Dihydroxymethyl-2,2-dimethyl dioxolane; L(+)-2,2-Dimethyl-1,3-dioxolane-4,5-dimethanol
- CAS编号50622-09-8
- MFCD编号:MFCD00063761
- EINECS号:256-658-6
- 分子式:C7H14O4
- 分子量:162.18
- 产品CID: 1494366
- 产品分类生物化工 → 糖类化合物 → 单糖
上下游产品
CAS号37031-29-1 (-)-二甲基-2,3-邻异丙... | CAS号59779-75-8 (R,R)-O,O-异丙基酒石酸二乙酯 | CAS号104863-91-4 (4R,5R)-methyl ... | CAS号108817-96-5 [(4S,5S)-5-({[(... | CAS号83529-40-2 (4R,5R)-2,2-dim... | CAS号81327-47-1 (4R,5R)-2,2-dim... | CAS号77-76-9 2,2-二甲氧基丙烷 | CAS号98-88-4 苯甲酰氯 | CAS号32305-98-9 异丙烯基-2,3-二羟基-1,... | CAS号37002-45-2 (-)-1,4-二-O-甲苯磺... | CAS号70831-49-1 (2S,3S)-2,3-(pr... | CAS号2319-57-5 L-苏丁醇 | CAS号149-32-6 赤藓糖醇 | CAS号58342-57-7 (+)-反式-4 5-双(碘甲...(4R,5R)-4,5-二乙氧基羰基-2,2-二甲基二氧置于lithium Aluminium Tetrahydride,Sodium Hydroxide,水体系中,用 四氢呋喃 作为反应溶剂,化学反应 2.5H,以94%的收率获得产物(4S,5S)-2,2-二甲基-1,3-二氧戊环-4,5-二甲醇
参考文献:旋光性柔性系链在低聚(亚苯基乙炔)中的螺旋扭曲感偏
标题:旋光性柔性系链在低聚(亚苯基乙炔)中的螺旋扭曲感偏
摘要:合成了一系列束缚的亚苯基亚乙炔基低聚物,它们经历了从无规卷曲到螺旋的溶剂依赖性构象转变.在(+)-酒石酸衍生的系链上使用三甲基甲硅烷基醚保护基导致形成具有大的扭曲感的螺旋.相反,异亚丙基缩酮保护基或没有保护基不仅对螺旋分辨无效,甚至可能抑制螺旋的形成.
DOI:10.1021/ol9912074
海关参考信息
- 2905122000-异丙醇
2905310000-1,2-乙二醇
2905320000-1,2-丙二醇
2905399001-1,3-丙二醇 - 💡 提示:海关信息按照顺序优先匹配,如需确认的海关信息,请参考相关资料。
- 详情请参考:📖 海关编码查询和海关进出口税则
专利信息
专利号:US-7772278-B2
优先权日:1999-03-01
标 题:Nitrosated and nitrosylated prostaglandins, compositions and methods of use
发明人:GARVEY DAVID S; GASTON RICKY D; LETTS L GORDON; DE TEJADA INIGO SAENZ; TAM SANG WILLIAM; WORCEL MANUEL
权利人:NITROMED INC
摘要:The invention describes novel nitrosated and/or nitrosylated prostaglandins, and novel compositions comprising at least one nitrosated and/or nitrosylated prostaglandin, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one vasoactive agent. The invention also provides novel compositions comprising at least one prostaglandin and at least one S-nitrosothiol compound, and, optionally, at least one vasoactive agent. The prostaglandin is preferably a prostaglandin E 1 compound, more preferably alprostadil, and the S-nitrosothiol compound is preferably S-nitrosoglutathione. The invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing cerebrovascular disorders, cardiovascular disorders, benign prostatic hyperplasia (BPH), glaucoma, peptic ulcers or for inducing abortions.